Thoratec Laboratories THOR
-
Thoratec Beats Big in 1Q, but Keeps Outlook
On Tuesday, Thoratec Laboratories THOR reported first-quarter results that ..... hours Tuesday. During the first quarter, Thoratec reported 27% sales growth to $127 million ..... lead to a modestly higher valuation for Thoratec .
-
Thoratec's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Thoratec Corporation ( THOR ) Q1 2012 Earnings Call May 1, 2012 4:30 pm ET Executives Taylor Harris ..... Securities Inc. Presentation Operator Good day, and welcome to the Thoratec Corporation Earnings Conference Call. Today’s conference is being …
-
Thoratec Competitor Gets FDA Panel Nod
On Wednesday, Thoratec Laboratories ' THOR key competitor in chronic ventricular ..... it often does, and we believe Thoratec 's HeartMate II device will face ..... HeartWare's device will likely end Thoratec 's firm grip on the U.S. chronic …
-
JPMorgan weighs in on Neutral-rated Thoratec ([[ THOR ]] -4.5%) after the firm recalled its HeartMate device prompting a rapid-fire selloff. Analysts with JP call the action a "non-event" since the ...
JPMorgan weighs in on Neutral-rated Thoratec ( THOR -4.5% ) after the firm recalled its HeartMate device prompting a rapid-fire selloff. Analysts with JP call the action a …
-
New Morningstar Analyst Report - Thoratec Laboratories
… chronic VAD that could steal share from Thoratec 's HeartMate II during the next few ..... looks like a very large opportunity. If Thoratec can address this market with HeartMate ..... many firms dependent on new devices, Thoratec 's financial position remains solid …
-
Piper Jaffray weighs in on Thoratec ([[ THOR ]] +11.2%) by upgrading the shares to Overweight on its strong earnings report, noting the recent quarter shows surprising unit growth.
Piper Jaffray weighs in on Thoratec ( THOR +11.2% ) by upgrading the shares to Overweight on its strong earnings report, noting the recent quarter shows surprising unit growth. Post your comment!
-
Shares of Thoratec ([[ THOR ]] +15.6%) extend gains from AH trading off of the firm's Q4 earnings beat and upward revision to FY12 guidance. The firm's CEO says in an earnings CC that revenue growth ...
Shares of Thoratec ( THOR +15.6% ) extend gains from AH trading off of the firm's Q4 earnings beat and upward revision to FY12 guidance. The firm's CEO says in an earnings CC that revenue growth was led by the HeartMate and CentiMag product lines. Post your comment!
-
Thoratec Beats on Bottom Line, Projects In-Line 2012
Thoratec Laboratories THOR met our top-line growth expectations ..... per share grew 36% to $0.38. Thoratec 's HeartMate II remained the key ..... surrounding the HeartWare device and Thoratec 's own market expansion tactics appear …
-
Thoratec's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Thoratec Corporation ( THOR ) Q4 2011 Earnings Call February 8, 2012 4:30 pm ET Executives Taylor ..... Jashnani – UBS Presentation Operator Good day, and welcome to the Thoratec Corporation Fourth Quarter and Fiscal Year 2011 Earnings Results Conference …
-
Thoratec ( THOR ): Q4 EPS of $0.38 beats by $0.05. Revenue of $109.4M (+12.1% Y/Y) beats by $2M. Shares +6.4% AH. (PR)
Thoratec ( THOR ): Q4 EPS of $0.38 beats by $0.05 . Revenue of $109.4M (+12.1% Y/Y) beats by $2M . Shares +6.4% AH. ( PR ) Post your comment!